1. Home
  2. NRT vs CING Comparison

NRT vs CING Comparison

Compare NRT & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRT

North European Oil Royality Trust

HOLD

Current Price

$8.69

Market Cap

67.2M

Sector

Energy

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$4.79

Market Cap

59.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRT
CING
Founded
1975
2012
Country
United States
United States
Employees
N/A
14
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.2M
59.3M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
NRT
CING
Price
$8.69
$4.79
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
41.3K
355.4K
Earning Date
05-29-2026
05-08-2026
Dividend Yield
10.18%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.09
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.76
$3.16
52 Week High
$10.49
$11.89

Technical Indicators

Market Signals
Indicator
NRT
CING
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NRT
CING

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: